Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer

Richard Castillo, Ngoc Pham, Sobiya Ansari, Dmitriy Meshkov, Sarah Castillo, Min Li, Adenike Olanrewaju, Brian Hobbs, Edward Castillo, Thomas Guerrero

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: A retrospective analysis is performed to determine if pre-treatment [18 F]-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) image derived parameters can predict radiation pneumonitis (RP) clinical symptoms in lung cancer patients. Methods and Materials: We retrospectively studied 100 non-small cell lung cancer (NSCLC) patients who underwent FDG PET/CT imaging before initiation of radiotherapy (RT). Pneumonitis symptoms were evaluated using the Common Terminology Criteria for Adverse Events version 4.0 (CTCAEv4) from the consensus of 5 clinicians. Using the cumulative distribution of pre-treatment standard uptake values (SUV) within the lungs, the 80th to 95th percentile SUV values (SUV80 to SUV95) were determined. The effect of pre-RT FDG uptake, dose, patient and treatment characteristics on pulmonary toxicity was studied using multiple logistic regression. Results: The study subjects were treated with 3D conformal RT (n = 23), intensity modulated RT (n = 64), and proton therapy (n = 13). Multiple logistic regression analysis demonstrated that elevated pre-RT lung FDG uptake on staging FDG PET was related to development of RP symptoms after RT. A patient of average age and V30 with SUV95 = 1.5 was an estimated 6.9 times more likely to develop grade ≥ 2 radiation pneumonitis when compared to a patient with SUV95 = 0.5 of the same age and identical V30. Receiver operating characteristic curve analysis showed the area under the curve was 0.78 (95% CI = 0.69 - 0.87). The CT imaging and dosimetry parameters were found to be poor predictors of RP symptoms. Conclusions: The pretreatment pulmonary FDG uptake, as quantified by the SUV95, predicted symptoms of RP in this study. Elevation in this pre-treatment biomarker identifies a patient group at high risk for post-treatment symptomatic RP.

Original languageEnglish (US)
Article number74
JournalRadiation Oncology
Volume9
Issue number1
DOIs
StatePublished - Mar 13 2014
Externally publishedYes

Fingerprint

Radiation Pneumonitis
Lung Neoplasms
Radiotherapy
Lung
Logistic Models
Proton Therapy
Conformal Radiotherapy
Therapeutics
Intensity-Modulated Radiotherapy
Fluorodeoxyglucose F18
Deoxyglucose
Terminology
ROC Curve
Non-Small Cell Lung Carcinoma
Area Under Curve
Pneumonia
Biomarkers
Regression Analysis

Keywords

  • Imaging biomarker
  • NSCLC
  • PET/CT
  • Radiation pneumonitis
  • Standard uptake value
  • Thoracic radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Castillo, R., Pham, N., Ansari, S., Meshkov, D., Castillo, S., Li, M., ... Guerrero, T. (2014). Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer. Radiation Oncology, 9(1), [74]. https://doi.org/10.1186/1748-717X-9-74

Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer. / Castillo, Richard; Pham, Ngoc; Ansari, Sobiya; Meshkov, Dmitriy; Castillo, Sarah; Li, Min; Olanrewaju, Adenike; Hobbs, Brian; Castillo, Edward; Guerrero, Thomas.

In: Radiation Oncology, Vol. 9, No. 1, 74, 13.03.2014.

Research output: Contribution to journalArticle

Castillo, R, Pham, N, Ansari, S, Meshkov, D, Castillo, S, Li, M, Olanrewaju, A, Hobbs, B, Castillo, E & Guerrero, T 2014, 'Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer', Radiation Oncology, vol. 9, no. 1, 74. https://doi.org/10.1186/1748-717X-9-74
Castillo R, Pham N, Ansari S, Meshkov D, Castillo S, Li M et al. Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer. Radiation Oncology. 2014 Mar 13;9(1). 74. https://doi.org/10.1186/1748-717X-9-74
Castillo, Richard ; Pham, Ngoc ; Ansari, Sobiya ; Meshkov, Dmitriy ; Castillo, Sarah ; Li, Min ; Olanrewaju, Adenike ; Hobbs, Brian ; Castillo, Edward ; Guerrero, Thomas. / Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer. In: Radiation Oncology. 2014 ; Vol. 9, No. 1.
@article{b0b0e345225e4d1dbed7eafee0d2b3c6,
title = "Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer",
abstract = "Background: A retrospective analysis is performed to determine if pre-treatment [18 F]-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) image derived parameters can predict radiation pneumonitis (RP) clinical symptoms in lung cancer patients. Methods and Materials: We retrospectively studied 100 non-small cell lung cancer (NSCLC) patients who underwent FDG PET/CT imaging before initiation of radiotherapy (RT). Pneumonitis symptoms were evaluated using the Common Terminology Criteria for Adverse Events version 4.0 (CTCAEv4) from the consensus of 5 clinicians. Using the cumulative distribution of pre-treatment standard uptake values (SUV) within the lungs, the 80th to 95th percentile SUV values (SUV80 to SUV95) were determined. The effect of pre-RT FDG uptake, dose, patient and treatment characteristics on pulmonary toxicity was studied using multiple logistic regression. Results: The study subjects were treated with 3D conformal RT (n = 23), intensity modulated RT (n = 64), and proton therapy (n = 13). Multiple logistic regression analysis demonstrated that elevated pre-RT lung FDG uptake on staging FDG PET was related to development of RP symptoms after RT. A patient of average age and V30 with SUV95 = 1.5 was an estimated 6.9 times more likely to develop grade ≥ 2 radiation pneumonitis when compared to a patient with SUV95 = 0.5 of the same age and identical V30. Receiver operating characteristic curve analysis showed the area under the curve was 0.78 (95{\%} CI = 0.69 - 0.87). The CT imaging and dosimetry parameters were found to be poor predictors of RP symptoms. Conclusions: The pretreatment pulmonary FDG uptake, as quantified by the SUV95, predicted symptoms of RP in this study. Elevation in this pre-treatment biomarker identifies a patient group at high risk for post-treatment symptomatic RP.",
keywords = "Imaging biomarker, NSCLC, PET/CT, Radiation pneumonitis, Standard uptake value, Thoracic radiotherapy",
author = "Richard Castillo and Ngoc Pham and Sobiya Ansari and Dmitriy Meshkov and Sarah Castillo and Min Li and Adenike Olanrewaju and Brian Hobbs and Edward Castillo and Thomas Guerrero",
year = "2014",
month = "3",
day = "13",
doi = "10.1186/1748-717X-9-74",
language = "English (US)",
volume = "9",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer

AU - Castillo, Richard

AU - Pham, Ngoc

AU - Ansari, Sobiya

AU - Meshkov, Dmitriy

AU - Castillo, Sarah

AU - Li, Min

AU - Olanrewaju, Adenike

AU - Hobbs, Brian

AU - Castillo, Edward

AU - Guerrero, Thomas

PY - 2014/3/13

Y1 - 2014/3/13

N2 - Background: A retrospective analysis is performed to determine if pre-treatment [18 F]-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) image derived parameters can predict radiation pneumonitis (RP) clinical symptoms in lung cancer patients. Methods and Materials: We retrospectively studied 100 non-small cell lung cancer (NSCLC) patients who underwent FDG PET/CT imaging before initiation of radiotherapy (RT). Pneumonitis symptoms were evaluated using the Common Terminology Criteria for Adverse Events version 4.0 (CTCAEv4) from the consensus of 5 clinicians. Using the cumulative distribution of pre-treatment standard uptake values (SUV) within the lungs, the 80th to 95th percentile SUV values (SUV80 to SUV95) were determined. The effect of pre-RT FDG uptake, dose, patient and treatment characteristics on pulmonary toxicity was studied using multiple logistic regression. Results: The study subjects were treated with 3D conformal RT (n = 23), intensity modulated RT (n = 64), and proton therapy (n = 13). Multiple logistic regression analysis demonstrated that elevated pre-RT lung FDG uptake on staging FDG PET was related to development of RP symptoms after RT. A patient of average age and V30 with SUV95 = 1.5 was an estimated 6.9 times more likely to develop grade ≥ 2 radiation pneumonitis when compared to a patient with SUV95 = 0.5 of the same age and identical V30. Receiver operating characteristic curve analysis showed the area under the curve was 0.78 (95% CI = 0.69 - 0.87). The CT imaging and dosimetry parameters were found to be poor predictors of RP symptoms. Conclusions: The pretreatment pulmonary FDG uptake, as quantified by the SUV95, predicted symptoms of RP in this study. Elevation in this pre-treatment biomarker identifies a patient group at high risk for post-treatment symptomatic RP.

AB - Background: A retrospective analysis is performed to determine if pre-treatment [18 F]-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) image derived parameters can predict radiation pneumonitis (RP) clinical symptoms in lung cancer patients. Methods and Materials: We retrospectively studied 100 non-small cell lung cancer (NSCLC) patients who underwent FDG PET/CT imaging before initiation of radiotherapy (RT). Pneumonitis symptoms were evaluated using the Common Terminology Criteria for Adverse Events version 4.0 (CTCAEv4) from the consensus of 5 clinicians. Using the cumulative distribution of pre-treatment standard uptake values (SUV) within the lungs, the 80th to 95th percentile SUV values (SUV80 to SUV95) were determined. The effect of pre-RT FDG uptake, dose, patient and treatment characteristics on pulmonary toxicity was studied using multiple logistic regression. Results: The study subjects were treated with 3D conformal RT (n = 23), intensity modulated RT (n = 64), and proton therapy (n = 13). Multiple logistic regression analysis demonstrated that elevated pre-RT lung FDG uptake on staging FDG PET was related to development of RP symptoms after RT. A patient of average age and V30 with SUV95 = 1.5 was an estimated 6.9 times more likely to develop grade ≥ 2 radiation pneumonitis when compared to a patient with SUV95 = 0.5 of the same age and identical V30. Receiver operating characteristic curve analysis showed the area under the curve was 0.78 (95% CI = 0.69 - 0.87). The CT imaging and dosimetry parameters were found to be poor predictors of RP symptoms. Conclusions: The pretreatment pulmonary FDG uptake, as quantified by the SUV95, predicted symptoms of RP in this study. Elevation in this pre-treatment biomarker identifies a patient group at high risk for post-treatment symptomatic RP.

KW - Imaging biomarker

KW - NSCLC

KW - PET/CT

KW - Radiation pneumonitis

KW - Standard uptake value

KW - Thoracic radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84899151495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899151495&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-9-74

DO - 10.1186/1748-717X-9-74

M3 - Article

VL - 9

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 74

ER -